Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Completed · Phase 4

Conditions studied: Alzheimer's Disease

In brief

This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.

Key facts

Study ID: NCT01703702
Run by: Avid Radiopharmaceuticals
People needed: 641
Starts: 2012-10-01
Expected to finish: 2015-04-01
Last updated by the study team: 2016-08-17

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients may be enrolled in the mild impairment (not demented) group if the following criteria are met:
Males or females ≥ 50 to <= 90 years of age.
Have cognitive decline verified by a study partner or cognitive impairment verified by the study physician.
Have a study partner who provides separate consent and is willing to accompany the patient on all of the study visits.
Have an MMSE score of 24 to 30 inclusive.
Can tolerate a 10-minute PET scan.
Have the ability to cooperate and comply with all study procedures.
Have an enrolling physician who has less than high confidence in their diagnosis for the patient related to the cognitive decline at the time of enrollment.
Ability to provide informed consent for study procedures.
Patients may be enrolled in the dementia group if the following criteria are met:
Are males or females ≥ 50 to <= 90 years of age.
Meet clinical criteria for dementia.
Have a caregiver who provides separate consent and is willing to accompany the patient on all of the study visits.
Have an MMSE score of 16 to 24 inclusive.
Have not received a clinical examination and/or laboratory test results that strongly indicates a non-neurodegenerative cause for the patients cognitive impairment.
Can tolerate a 10-minute PET scan.
Have the ability to cooperate and comply with all study procedures.
Have an enrolling physician who has less than high confidence in their diagnosis for the patient related to the cognitive decline at the time of enrollment.
Ability to provide informed consent for study procedures. (If the patient is incapable of giving informed consent, the patient's legal representative may consent on behalf of the patient but the patient must still confirm assent. This person may serve as the study partner as well).

You may not qualify if…

Patients will be excluded from enrollment if they:
Have a current serious or unstable illness;
The patient or enrolling physician knows the result of a previous amyloid imaging scan;
The patient has a known brain lesion, pathology or alternative diagnosis that strongly explains the patient's clinical presentation;
Are receiving any investigational medications, or have participated in a trial with investigational medications within the last 30 days;
Have ever participated in an experimental study with an amyloid targeting agent (e.g. anti-amyloid immunotherapy, γ -secretase or β -secretase inhibitor) unless it can be documented that the patient received only placebo during the course of the trial;
Have had a radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session; or
Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception.
Patients will also be excluded from enrollment if their enrolling physician:
Does not consider Alzheimer's disease as a potential cause of the patient's cognitive decline.
Is not the primary physician taking care of the patient with respect to the management of their cognitive impairment.
Cannot categorize the patient as either: a) having a documented and completed evaluation for cognitive decline within the past 18 months old; or b) currently undergoing evaluation for cognitive decline.
Is unwilling to suspend all testing and other evaluation procedures between the time of the baseline evaluation of the enrolling physician's diagnosis and management plan and the time the completion of the PET scan.

Where it is running

Research Site — Phoenix, Arizona, United States
Research Site — Scottsdale, Arizona, United States
Research Site — Sun City, Arizona, United States
Research Site — Clearwater, Florida, United States
Research Site — Miami Beach, Florida, United States
Research Site — Orlando, Florida, United States
Research Site — West Palm Beach, Florida, United States
Research Site — Shreveport, Louisiana, United States
Research Site — Boston, Massachusetts, United States
Research Site — Chestnut Hill, Massachusetts, United States
Research Site — Quincy, Massachusetts, United States
Research Site — Las Vegas, Nevada, United States
Research Site — Las Vegas, Nevada, United States
Research Site — Patchogue, New York, United States
Research Site — Durham, North Carolina, United States
Research Site — Greensboro, North Carolina, United States
Research Site — Providence, Rhode Island, United States
Research Site — Providence, Rhode Island, United States
Research Site — Salt Lake City, Utah, United States
Research Site — Bennington, Vermont, United States
Research Site — Amiens, France
Research Site — Bordeaux, France
Research Site — Bron, France
Research Site — Dijon, France
Research Site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.